Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

Mechanism of Action

THE FIRST AND ONLY ADC THAT TARGETS TROP-2 AS A WAY INTO mTNBC TUMORS

TRODELVY binds to the antigen Trop-2 and delivers and concentrates a potent cytotoxic into tumor tissue1

  • Trop-2 is a surface protein highly expressed by many cancers, including approximately 90% of TNBC tumors2*
  • Trop-2 biomarker testing is not required for use with TRODELVY

Take a closer look at how TRODELVY is thought to work

The proposed mechanism of action is based on preclinical data, which may not correlate with clinical outcomes.

The proposed mechanism of action (MOA) of TRODELVYᵀᴹ that highlights, a humanized monoclonal antibody, cytotoxicity, and a hydrolysable linker
 

Humanized monoclonal antibody

Binds to Trop-2, the trophoblast cell-surface antigen-2
 

Hydrolysable linker

  • Links the humanized monoclonal antibody to SN-38
  • Hydrolysis of the linker releases SN-38 to kill tumor cells
 

Cytotoxic

The payload of TRODELVY is SN-38, a topoisomerase 1 inhibitor that prevents repair of DNA damage and leads to apoptosis and cell death

TRODELVY has a high drug-to-antibody ratio, with an average of 7 to 8 molecules of SN-38 per antibody molecule

 
  • Antibody-drug conjugates (ADCs) use a monoclonal antibody to deliver an attached cytotoxic drug into tumors3
  • Once inside the tumor, the linker connecting the antibody to the cytotoxic is cleaved, releasing the active drug3

*As measured by immunohistochemical (IHC) assay.

References: 1. Goldenberg D, Cardillo TM, Govindan S, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496-22512. 2. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141-2148. 3. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):1-20